- Home
- MYTE vs CBLL Comparison
MYTE vs CBLL Comparison
Compare MYTE & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYTE
- CBLL
- Stock Information
- Founded
- MYTE 2006
- CBLL 2014
- Country
- MYTE Germany
- CBLL United States
- Employees
- MYTE N/A
- CBLL N/A
- Industry
- MYTE Catalog/Specialty Distribution
- CBLL
- Sector
- MYTE Consumer Discretionary
- CBLL
- Exchange
- MYTE Nasdaq
- CBLL Nasdaq
- Market Cap
- MYTE 800.6M
- CBLL 762.0M
- IPO Year
- MYTE 2021
- CBLL 2024
- Fundamental
- Price
- MYTE $10.72
- CBLL $24.69
- Analyst Decision
- MYTE Buy
- CBLL Strong Buy
- Analyst Count
- MYTE 2
- CBLL 5
- Target Price
- MYTE $4.88
- CBLL $33.25
- AVG Volume (30 Days)
- MYTE 187.0K
- CBLL 151.6K
- Earning Date
- MYTE 02-11-2025
- CBLL 02-25-2025
- Dividend Yield
- MYTE N/A
- CBLL N/A
- EPS Growth
- MYTE N/A
- CBLL N/A
- EPS
- MYTE N/A
- CBLL N/A
- Revenue
- MYTE $912,559,271.00
- CBLL $60,041,000.00
- Revenue This Year
- MYTE $11.39
- CBLL $44.86
- Revenue Next Year
- MYTE $9.55
- CBLL $26.56
- P/E Ratio
- MYTE N/A
- CBLL N/A
- Revenue Growth
- MYTE 12.41
- CBLL 131.62
- 52 Week Low
- MYTE $2.63
- CBLL $18.69
- 52 Week High
- MYTE $12.50
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- MYTE 56.40
- CBLL N/A
- Support Level
- MYTE $10.71
- CBLL N/A
- Resistance Level
- MYTE $12.06
- CBLL N/A
- Average True Range (ATR)
- MYTE 0.85
- CBLL 0.00
- MACD
- MYTE -0.00
- CBLL 0.00
- Stochastic Oscillator
- MYTE 54.12
- CBLL 0.00
About MYTE MYT Netherlands Parent B.V. each representing one
MYT Netherlands Parent BV is a luxury e-commerce platform. The company offers luxury fashion wear for men, women, and kids. Also, the company sells shoes, bags, and accessories. The company operates in two segments which include the online segment and Retail store segments in which the majority of its revenue is generated from the Online segment.
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.